Direct-to-Discovery: Extending Direct-to-Biology paradigms to accelerate oncology drug discovery

Direct-to-Discovery: Accelerating Oncology Drug Discovery

Drug discovery timelines are often extended by bottlenecks between chemistry, biology and downstream decision-making. Traditional workflows rely on purified compounds and sequential data generation, slowing progression from hit identification to candidate nomination. Our direct-to-discovery approach removes these barriers by extending direct-to-biology paradigms beyond biophysics, enabling rapid, data-rich decision-making earlier in discovery.

Extending established discovery workflows

Direct-to methodologies are typically associated with early biophysical screening such as SPR, where crude reaction mixtures can be assessed without full purification. While effective for assessing target binding, these methods alone do not capture functional activity or developability risk.

By expanding this paradigm to include function biology, structure validation and DMPK insight, we enable teams to generate richer datasets directly from unpurified compounds and move forward with greater confidence.

A joined-up direct-to platform

Our platform enables:

• Functional biochemical and cellular readouts directly from crude reaction mixtures
• Rapid structural validation through direct-to-crystallography from HTS and design libraries
• Early physicochemical and DMPK insight, supporting smarter triage decisions
• Seamless integration with high-throughput chemistry and AI-driven design

Together, these capabilities shorten DMTA cycles, reduce resynthesis burden and compress timelines from hit discovery to lead optimization.

Impact on oncology drug discovery

Applied within oncology programs, this approach has demonstrated the ability to significantly accelerate progression from hit finding to pre-candidate nomination. By generating holistic datasets earlier, teams can focus resources on the most promising compounds sooner.

The result is faster timelines, better-informed decision and reduced program risk.

Download the poster to explore how our direct-to-discovery approach extends direct-to-biology methods to accelerate oncology drug discovery, supported by real data and case study examples.